Ritter Pharmaceuticals Inc (RTTR) Expected to Announce Earnings of -$0.54 Per Share

Wall Street brokerages predict that Ritter Pharmaceuticals Inc (NASDAQ:RTTR) will post earnings per share (EPS) of ($0.54) for the current quarter, according to Zacks. Zero analysts have provided estimates for Ritter Pharmaceuticals’ earnings. Ritter Pharmaceuticals reported earnings of ($0.71) per share in the same quarter last year, which would indicate a positive year over year growth rate of 23.9%. The company is scheduled to announce its next quarterly earnings results on Tuesday, August 13th.

On average, analysts expect that Ritter Pharmaceuticals will report full-year earnings of ($1.55) per share for the current financial year. For the next year, analysts expect that the business will post earnings of ($0.65) per share. Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Ritter Pharmaceuticals.

Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.14.

A number of analysts have weighed in on the stock. ValuEngine upgraded shares of Ritter Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Zacks Investment Research lowered shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th.

A number of large investors have recently added to or reduced their stakes in RTTR. Virtu Financial LLC bought a new stake in Ritter Pharmaceuticals during the 1st quarter valued at about $46,000. Vanguard Group Inc grew its stake in shares of Ritter Pharmaceuticals by 300.6% in the third quarter. Vanguard Group Inc now owns 56,210 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 42,180 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Ritter Pharmaceuticals by 264.6% in the first quarter. Renaissance Technologies LLC now owns 128,418 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 93,200 shares during the period. Institutional investors and hedge funds own 9.39% of the company’s stock.

NASDAQ:RTTR traded up $0.01 on Thursday, reaching $0.86. 108,600 shares of the stock traded hands, compared to its average volume of 523,461. The firm has a market cap of $7.69 million, a P/E ratio of -0.23 and a beta of 1.46. Ritter Pharmaceuticals has a 12 month low of $0.47 and a 12 month high of $4.00.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.

Featured Article: Determine Your Level of Risk Tolerance

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit